Clinical Trial

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

Name: A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) — clinical trial record (NCT07650357)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.

Trial Details

NCT Number	NCT07650357
Lead Sponsor	Clasp Therapeutics, Inc.
Conditions	Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Enrollment	140 participants
Start Date	2026-07
Primary Completion	2029-05 (estimated)
Study Completion	2029-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-16